Shilpa Medicare Valuation

Is 530549 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 530549 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 530549 (₹911) is trading above our estimate of fair value (₹64.5)

Significantly Below Fair Value: 530549 is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 530549?

Key metric: As 530549 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 530549. This is calculated by dividing 530549's market cap by their current earnings.
What is 530549's PE Ratio?
PE Ratio	129.5x
Earnings	₹610.83m
Market Cap	₹79.08b

530549 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	6.9x
Enterprise Value/EBITDA	29.3x
PEG Ratio	1.7x

Price to Earnings Ratio vs Peers

How does 530549's PE Ratio compare to its peers?

The above table shows the PE ratio for 530549 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	40.1x
500126 Procter & Gamble Health	38.8x	11.3%	₹84.5b
531599 FDC	25.1x	n/a	₹79.6b
SUPRIYA Supriya Lifescience	41.2x	14.3%	₹64.9b
BLUEJET Blue Jet Healthcare	55.1x	24.1%	₹92.5b
530549 Shilpa Medicare	129.5x	77.1%	₹79.1b

Price-To-Earnings vs Peers: 530549 is expensive based on its Price-To-Earnings Ratio (129.5x) compared to the peer average (36.3x).

Price to Earnings Ratio vs Industry

How does 530549's PE Ratio compare vs other companies in the IN Pharmaceuticals Industry?

2 Companies	Price / Earnings	Estimated Growth	Market Cap
INDSWFTLAB Ind-Swift Laboratories	1.6x	n/a	US$70.43m
524652 Ind-Swift	2x	n/a	US$13.12m

No more companies available in this PE range

2 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Earnings vs Industry: 530549 is expensive based on its Price-To-Earnings Ratio (129.5x) compared to the Indian Pharmaceuticals industry average (31.7x).

Price to Earnings Ratio vs Fair Ratio

What is 530549's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

530549 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	129.5x
Fair PE Ratio	91.9x

Price-To-Earnings vs Fair Ratio: 530549 is expensive based on its Price-To-Earnings Ratio (129.5x) compared to the estimated Fair Price-To-Earnings Ratio (91.9x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 530549 forecast and predictions for the stock price in 12 month’s time.
Date	Share Price	Average 1Y Price Target	Dispersion	High	Low	1Y Actual price	Analysts
Current	₹911.00	₹1,208.00 +32.6%	26.2%	₹1,525.00	₹891.00	n/a	2
Nov ’25	₹842.30	₹1,095.50 +30.1%	18.7%	₹1,300.00	₹891.00	n/a	2
Oct ’25	₹834.65	₹1,095.50 +31.3%	18.7%	₹1,300.00	₹891.00	n/a	2

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.

Discover undervalued companies

Caplin Point Laboratories

₹149.4b

Engages in the development, production, marketing, and export of generic pharmaceutical formulations and branded products in India.

CAPLIPOINT

₹1,963.75

0.6%

59.7%

Mercury Laboratories

₹1.1b

Develops, manufactures, markets, distributes, and sells pharmaceutical drugs, medicines, and formulations for mother and child healthcare in India and internationally.

538964

₹928.00

-1.7%

15.6%

Solara Active Pharma Sciences

₹38.4b

Manufactures, produces, processes, formulates, sells, imports, exports, merchandises, distributes, trades in, and deals in active pharmaceutical ingredients (API) in India, Asia Pacific, Europe, North America, South America, and internationally.

541540

₹798.40

5.3%

137.7%